Qualigen Therapeutics announces data from the Company’s poster presented at the American Association for Cancer Research, AACR, Annual Meeting 2023 held April 14-19 in Orlando, FL. The Company presented in vivo efficacy data regarding its QN-247 program, for which it is actively seeking partners. "These encouraging data demonstrate QN-247 may be an effective nano-immunotherapy against triple negative breast cancer. They are an important validation for our development approach, and we believe they will be meaningful as we actively seek opportunities around this compound," said Michael Poirier, Qualigen’s Chairman and CEO. Highlights from QN-247 Poster: Study authors had prepared QN-247 conjugates that build upon the legacy of the anti-proliferative DNA aptamer AS1411. . QN-247 is active in vitro against a variety of cancers including prostate cancer and Triple Negative Breast Cancer, and more potent than the anti-proliferative aptamer AS1411 itself. In addition, QN-247 is effective in vivo against a xenograft mouse TNBC model showing highly significant reductions in tumor volumes with no evidence of toxicity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on QLGN:
- Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL
- Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL
- Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office
- Qualigen Therapeutics granted patent for QN-302 by USPTO
- Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023